The North America Molecular Infectious Disease Testing Market is projected to grow from 5630 million USD in 2020 to 10450 million USD by 2035. The years 2020-2025 witness sharp growth due to increased demand for respiratory and multi-pathogen testing triggered by the COVID-19 pandemic. Post-2025, the market stabilizes yet maintains a robust upward trajectory, propelled by technological innovations, expansion in testing menus, and growing adoption across diverse healthcare settings. Ongoing investments in automation and next-generation technologies further fuel revenue expansion through the forecast period.
Read More - https://bussinessinsights.com/research-report/north-america-molecular-infectious-disease-testing-market
In 2025, Respiratory Diseases represent the largest application segment in the North America market, accounting for 38% of total demand. The continued burden of respiratory pathogens post-pandemic drives sustained demand for molecular assays in this area. Hospital-Acquired Infections garner 22%, reflecting hospitals’ emphasis on infection surveillance and prevention. HIV and Hepatitis testing together constitute 25% (HIV at 14% and Hepatitis at 11%) as molecular assays remain essential tools for management and monitoring of these chronic infections. Gastrointestinal Diseases capture 9%, with Others comprising the remaining 6%. Overall, the dominance of respiratory and hospital infection applications underlines the market’s focus on early detection and public health response.
Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-molecular-infectious-disease-testing-market
Who are the key players in North America Molecular Infectious Disease Testing Market industry?
The top five players in the North America Molecular Infectious Disease Testing Market include Roche Diagnostics, Abbott Laboratories, Bio-Rad Laboratories, Thermo Fisher Scientific, and Hologic Inc. These companies offer advanced molecular diagnostics platforms and are focused on innovation, strategic partnerships, and expanding their infectious disease testing portfolios across North America.
What is the North America Molecular Infectious Disease Testing Market growth?
The North America Molecular Infectious Disease Testing Market has witnessed significant growth, with recent estimates indicating a CAGR of approximately 7% from 2022 to 2028. Companies like Thermo Fisher Scientific are driving this growth through the launch of advanced real-time PCR and molecular diagnostic kits, addressing rising infectious disease incidences.
Which segment accounted for the largest North America Molecular Infectious Disease Testing Market share?
The respiratory diseases segment, including testing for influenza, RSV, and COVID-19, accounted for the largest market share. Heightened demand during the COVID-19 pandemic and persistent influenza outbreaks have fueled robust growth in this segment, as leading companies launch multiplex assays for rapid pathogen identification.
Thanks & Regards,
Manisha C
sales [at] bussinessinsights.com